SLC34A1 and hyperphosphatemia: By inhibiting FGFR1, Erdafitinib reduces FGF23 levels, which diminishes the inhibition of sodium-phosphate co-transporters in renal proximal tubules, thereby increasing renal phosphate reabsorption and resulting in hyperphosphatemia (Kommalapati et al., 2021).